'For the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Ajanta Pharma has increased 13.73% to Rs 1105.15 crore compared to quarter ended Dec 2022.  Operating profit margin has jumped from 17.45% to 28.42%, leading to 85.24% rise in operating profit to Rs 314.07 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 24.90% to 21.94%.   Purchase of finished goods cost fell from 4.01% to 3.61%.   Employee cost increased from 19.47% to 21.24%.   Other expenses fell from 34.46% to 24.38%.   

Other income fell 61.09% to Rs 13.59 crore.  PBIDT rose 60.24% to Rs 327.66 crore.  Provision for interest fell 12.32% to Rs 2.49 crore.  

PBDT rose 61.26% to Rs 325.17 crore.  Provision for depreciation rose 2.88% to Rs 34.26 crore.  

Profit before tax grew 72.81% to Rs 290.91 crore.  S...

• 

  (17-Aug-2024)

  AIA Engineering

  Net down 5% on lower sales

• 

  (17-Aug-2024)

  Voltas

  Net jump 159% on good operating show

• 

  (17-Aug-2024)

  ABB India

  Net up 50% on good operating show

• 

  (17-Aug-2024)

  NHPC

  Sales down 2%, net down 1%